Barclays analyst Luke Sergott raised the firm’s price target on Avantor (AVTR) to $26 from $25 and keeps an Overweight rating on the shares.

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Avantor (AVTR – Research Report), with a price target of ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, ...

Wall Street expects flat earnings compared to the year-ago quarter on lower revenues when Avantor, Inc. (AVTR) reports results for the quarter ended December 2024. While this widely-known consensus ...

RADNOR, PA — Avantor, Inc. (NYSE: AVTR) has announced a definitive agreement to sell its clinical services business to Audax ...

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes ...

UBS Group reissued their neutral rating on shares of Avantor (NYSE:AVTR – Free Report) in a research note published on Friday, Ratings reports. They currently have a $25.00 target price on the stock, ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release ...